Background: The infection with the hepatitis B virus represents a significant global health challenge with serious complexities like the failure of the liver and hepatocellular carcinoma. It results in an estimated mortality of 1.12 million cases in 2022. Aim of Study: This study aimed to use hepatitis B surface antigen and liver function tests as prediction markers for patients infected with the hepatitis B virus and compare them with viral load in Wasit Province, Iraq. Materials and Methods: This study involved 75 patients, both male and female, who made up the study population. Hepatitis B virus (HBV)-positive patients' samples were gathered from Al-Karama Teaching Hospital and the General Public Health Central Lab in Kut City between December 2023 and May 2024, in addition to 75 apparently healthy volunteers as a control group. The enzymatic liver biomarkers (the ALT, the AST, the ALP, and the TSB) were detected by utilizing the Roche Cobas C111 system, and the hepatitis B surface antigen was detected by utilizing the ELISA. Results: Both ELISA and viral load results were positive for all patients, and liver enzymes showed a significant and remarkable rise among the group of patients. Conclusion: The paper of research gives insight, as the utilization of ELISA is much more effective, and it could be used in monitoring the progress of HBV infection along with liver enzymes.
Madhi et al. (Wed,) studied this question.